Plain-English translation of NCT06594744 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial compares two ways to prevent a serious complication in patients with hepatocellular carcinoma (liver cancer) who have enlarged veins in their esophagus. One approach uses a procedure called endoscopic variceal ligation, where a doctor ties off these enlarged veins using an endoscope. The other approach uses a medication called , which is a beta-blocker pill that reduces pressure in the blood vessels and helps prevent bleeding.
Nearly half of liver cancer patients with these enlarged veins will experience dangerous bleeding without treatment, and this bleeding carries a very high risk of death. While guidelines suggest both approaches might work, there is limited evidence comparing them directly in liver cancer patients, so doctors need to know which option works better.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the endoscopic procedure or the medication. If assigned to the procedure, you will have treatments every 3 to 4 weeks until the veins are eliminated, followed by regular check-ups with endoscopy starting every 3 months and eventually annually. If assigned to the medication, you will take a daily pill (starting at a low dose and increasing as tolerated) and have regular clinic visits to monitor how you are doing. The trial will follow you for up to two years to see which approach better prevents bleeding.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Taiwan